Literature DB >> 25456375

FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply.

Volker Heinemann1, Sebastian Stintzing2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25456375     DOI： 10.1016/S1470-2045(14)71036-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.

Authors:  Manojkumar Bupathi; Christina Wu
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 2.  First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Authors:  Elena Elez; Guillem Argilés; Josep Tabernero
Journal:  Curr Treat Options Oncol       Date:  2015-11

Review 3.  DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.

Authors:  D J Weisenberger; G Liang; H-J Lenz
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

4.  Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Gastrointest Cancer       Date:  2016-06-30

5.  A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy.

Authors:  Young Mi Seol; Chae Hwa Kwon; So Jeong Lee; Seon Jin Lee; Yuri Choi; Young Jin Choi; Hyojeong Kim; Do Youn Park
Journal:  Transl Oncol       Date:  2018-11-16       Impact factor: 4.243
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.